• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:陈帅,梁燕文,林建梭,苏均宇,任建卫,刘义.LAG3剪接变异体对肝癌细胞增殖及索拉非尼耐药的影响[J].药学研究,2026,45(1):17-21,95[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2675次   下载 816次 本文二维码信息
码上扫一扫!
LAG3剪接变异体对肝癌细胞增殖及索拉非尼耐药的影响
陈帅1,梁燕文1,林建梭2,苏均宇3,任建卫4,刘义1
字体:加大+|默认|缩小-
(1.广东医科大学海洋与热带医学学院,广东 湛江 524023;2.广东医科大学基础医学院,广东 东莞 523808;3.广东医科大学药学院,广东 东莞 523808;4.深圳瑞科生物科技有限公司,广东 深圳 518100)
摘要:
目的 构建在肝癌细胞表达的免疫活化基因3(LAG3)剪接变异体稳转细胞株,探讨剪接变异体对肝癌细胞增殖及对索拉非尼耐药性的影响。方法 以Hep3B cDNA为模板,采用巢式PCR扩增LAG3基因,对琼脂糖凝胶电泳分离差异条带测序并与NCBI数据库中的LAG3转录变体对比,发现其相对人全长LAG3 mRNA缺少3号外显子(LAG3Δ3)。构建LAG3Δ3-pIGvetor重组质粒,通过慢病毒系统将重组质粒转染至Hep3B细胞,嘌呤霉素筛选后,利用RT-qPCR和Western blotting验证稳转细胞是否构建成功,MTT法评估细胞增殖及耐药性。结果 筛选后的Hep3B-LAG3Δ3细胞LAG3Δ3 mRNA及蛋白水平较对照Hep3B-NC细胞显著增高(P<0.000 1)。过表达LAG3Δ3细胞的增殖能力更强,其对索拉非尼的耐药性相比Hep3B-NC细胞有所增强(P<0.05)。结论 成功构建Hep3B-LAG3Δ3剪接变异体稳转细胞株,LAG3Δ3可促进肝癌细胞增殖,减弱肝癌细胞对索拉非尼的敏感性。
关键词:  淋巴细胞活化因子3  剪接变异体  稳转细胞  耐药  索拉非尼
DOI:10.13506/j.cnki.jpr.2026.01.003
基金项目:
出版日期:2026-01-26
The impact of LAG3 splice variants on hepatocellular carcinoma cell proliferat-ion and sorafenib resistance
CHEN Shuai1,LIANG Yanwen1,LIN Jiansuo2,SUN Junyu3,REN Jianwei4,LIU Yi1
(1.School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang, 524023, China 2. School of Basic Medical Sciences, Guangdong Medical University, Dongguan 523808, China 3. School of Pharmacy, Guangdong Medical University, Dongguan 523808, China 4. Shenzhen Reke Biotechnology Co., LTD., Shenzhen, 518100, China)
Abstract:
Objective Objective To construct a stable cell line expressing splice variants of immune activation gene 3 (LAG3) in hepatocellular carcinoma cells and to investigate the effects of splice variants on the proliferation of hepatocellular carcinoma cells and sorafenib resistance.Methods Hep3B cDNA was used as a template to amplify the LAG3 gene by nested PCR. The differential bands separated by agarose gel electrophoresis were sequenced and compared with the LAG3 transcript variants in the NCBI database. It was found that it lacked exon 3 (LAG3Δ3) relative to the full-length human LAG3 mRNA. The LAG3Δ3-pIGvetor recombinant plasmid was constructed and transfected into Hep3B cells by lentiviral system. After puromycin selection, RT-qPCR and Western blotting were used to verify whether the stable cell line was successfully constructed. The cell proliferation and drug resistance were evaluated by MTT method. Results The levels of LAG3Δ3 mRNA and protein in the selected Hep3B-LAG3Δ3 cells were significantly increased compared with those in the control Hep3B-NC cells (P<0.000 1). The proliferation ability of cells overexpressing LAG3Δ3 was stronger and their resistance to sorafenib was enhanced compared with Hep3B-NC cells (P<0.05).Conclusion Hep3B-LAG3Δ3 splicing variant stable cell line was successfully constructed. LAG3Δ3 can promote the proliferation of liver cancer cells and reduce the sensitivity of liver cancer cells to sorafenib.
Key words:  Lymphocyte activation gene 3  Splice variant  Stable transfection  Drug resistance
今日访问量:2657    总访问量:55339174
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司